Medical Properties Trust Earnings Call Transcripts
Fiscal Year 2026
-
Portfolio EBITDARM coverage remained stable at 2.5x, with strong post-acute and general acute results offset by U.K. behavioral health challenges due to NHS funding cuts. Normalized FFO was $0.14 per share, and annualized cash rent is on track to exceed $1 billion by year-end.
Fiscal Year 2025
-
Portfolio EBITDARM coverage improved to 2.6x year-over-year, with strong gains in acute and post-acute segments. Normalized FFO reached $0.18 per share for Q4, and the company expects to surpass $1 billion in annualized cash rent by end of 2026.
-
Tenants delivered strong operational and financial results, with significant EBITDARM growth across segments and robust international performance. Asset sales, a new $150 million share repurchase program, and strategic refinancing support liquidity and future rent growth.
-
Q2 2025 featured strong rent growth from new tenants, robust international and U.S. operator performance, and successful refinancing activities. Normalized FFO was $0.14 per share, with asset sales and capital strategies supporting future growth.
-
Q1 2025 featured strong operational and financial performance, highlighted by a $2.5B bond issuance, improved EBITDARM coverage, and ramping cash rents from new tenants. Impairments and refinancing impacted results, but liquidity and outlook remain robust.
Fiscal Year 2024
-
Surpassed liquidity targets with $3B in transactions and secured $2.5B in bonds, covering debt maturities through 2026. Q4 saw a $413M net loss due to Prospect impairments, but portfolio fundamentals and operator diversification improved, with strong rent ramp-up expected.
-
Q3 2024 saw a global settlement with Steward, re-tenanting of 17 properties, and over $2.9B in asset sales. Despite a GAAP net loss and significant impairments, cash flow and liquidity remain strong, with stabilized rent and debt coverage expected to improve in 2025.
-
Q2 2024 saw strong operational trends and over $2.5B in liquidity transactions, exceeding targets. Despite a GAAP net loss and significant impairments, debt maturities for 2024 and 2025 are fully addressed, and the portfolio remains diversified and resilient.